Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

HBHarvard Bioscience, Inc.

35 indications, side-by-side phase, drug & LoA

$6.08

-0.56 (-8.43%)

B 69Pipeline Score Diagnostics · Commercial
Market Cap
25.21 M
EPS
-2.20
P/E Ratio
-
Value Trade
182.84 K
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    20.75 M

  • R&D Expenses

    2.33 M

  • Operating CF

    -662.00 K

  • Total Assets

    77.94 M

  • Total Liabilities

    67.89 M

  • Equity

    10.05 M

  • D/E Ratio

    12,345

2.76 %
Week
-15.56 %
1 Month
-6.83 %
3 Month
-0.53 %
6 Month
-92.08 %
5 Year
-91.4 %
All Time
Cash Data
Healthy

  • Cash Position

    7.10 M

  • Monthly Burn

    221.00 K

  • Runway

    31.1 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 12, 2026
Overview
Volume
30.53 K
52 Week Range
2.81 - 9.46
% held by Insiders
6.04 %
% held by Institutions
42.69 %
Enterprise Value
62.24 M
Total Shares
4.51 M
Short %
3.17 %
Float Shares
3.35 M
Company Description
HQ: 84 OCTOBER HILL RD, HOLLISTON,...
Employees:339
https://www.harvardbioscience....

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
B69
Pipeline Score
$378M
Pipeline Value
Valuation Signal
20
Drugs Scored
15.0x
rNPV / MCap
Top 94%
Micro Cap
(rank 55 of 905)
Percentile Rank
Harvard Bioscience, Inc. holds a solid B-grade pipeline (69/100), with $16.7B risk-adjusted pipeline value, led by Teduglutide in HIV (Phase 2), across $161B in total addressable markets.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Teduglutide
Small molecule		HIVPhase 2NCT0243132540% $3.3B COMPLETED 32 - -Jan 21, 2021 -Jun 12, 2023
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in HBIO
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
HBIO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
HBIO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
HBIO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
HBIO Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
HBIO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-08-21 0.00 0 - - - - - -
2026-08-21 0.00 0 - - - - - -
2026-08-21 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Harvard Bioscience, Inc. (HBIO) News & Alerts
-
Sunday, June 14, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How HBIO ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Substance Use Disorders #4 of 8 PHASE 2 SL-BUP + -BUP + -NTX
LLY ALT CMND
—0 CONTENDER
HIV / AIDS #6 of 14 PHASE 2 Nevirapine + Kaletra + Lamivudine + Zidovudine
MRK GILD GSK
—0 FOLLOWER
Major Depressive Disorder #17 of 31 PHASE 3 Antidepressant medication
CMPS NBIX JNJ
$12.0B 0 FOLLOWER